Rege Nephro is a biotech company that specializes in R&D, production, and marketing of renal disease therapeutics.
Rege Nephro has raised $15.2M in total funding. The most recent round was Series B. The last funding was announced in October 2024.
Rege Nephro's investors include Mitsubishi UFJ Capital, Global Brain Corporation, SMBC Venture Capital, JIC Venture Growth Investments, Senshu Ikeda Capital.
Rege Nephro is headquartered in Kyoto, Japan.
Rege Nephro is a biotech company that specializes in R&D, production, and marketing of renal disease therapeutics.
Rege Nephro is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rege Nephro — Funding & Investors." VCBacked, October 7, 2024, https://www.vcbacked.co/company/rege-nephro. Accessed July 19, 2026.
VCBacked. (2024). Rege Nephro — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/rege-nephro
{{cite web |title=Rege Nephro — Funding & Investors |url=https://www.vcbacked.co/company/rege-nephro |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated